Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation and re-treatment with pexidartinib in tenosynovial giant cell tumor
2020-000192-20Phase 4Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pexidartinib in tenosynovial giant cell tumor (TGCT) and giant cell tumor of tendon sheath (GCTTS) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Proportion of subjects who remain treatment-free at Month 12 and Proportion of subjects who remain treatment-free at Month 24. Started Jun 2020; status: completed.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)giant cell tumor of tendon sheath (GCTTS)
Beyond the preview
Go deeper on 2020-000192-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000192-20.